SIRPant Immunotherapeutics Overview
- Founded
- 2020
- Status
- Private
- Employees
- 4
- Latest Deal Type
- Early Stage VC
- Latest Deal Amount
- $1.5M
- Investors
- 1
SIRPant Immunotherapeutics General Information
Description
Developer of cancer-specific immunotherapy intended to focus on the development of novel autologous cell therapy for solid tumors. The company's technology employs an Adoptive Cell Therapy (ACT) approach to elicit tumor-specific T-cells resulting in a polyclonal immune response against multiple tumor antigens, helping doctors to treat solid tumors efficiently.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 1590 Bunker Court
- Chambersburg, PA 17202-8040
- United States
+1 (610) 000-0000
SIRPant Immunotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 30-Nov-2020 | $1.5M | 00.00 | Completed | Startup |
SIRPant Immunotherapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of cancer-specific immunotherapy intended to focus on the development of novel autologous cell therapy for sol
Biotechnology
Chambersburg, PA
4
As of 2021
00.00
0000000000 0
00.00
0000000
bore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi
0000 000000000
Philadelphia, PA
00
As of 0000
00000
00000000000
00000
00000000
cing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim venia
0000000000000
Windsor, United Kingdom
0000
00.00
0000-00-00
0000000000 0
0000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialSIRPant Immunotherapeutics Competitors (10)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Carisma Therapeutics | Venture Capital-Backed | Philadelphia, PA | 00 | 00000 | 00000000000 | 00000 |
| 0000000000 000000 | Venture Capital-Backed | Windsor, United Kingdom | 0000 | 0000000000 0 | 0000 | |
| 000 00000000 | Formerly VC-backed | Burlingame, CA | 00 | 00000 | 00000000 | 00000 |
| 0000 00000000 | Venture Capital-Backed | Brisbane, CA | 00 | 000.00 | 000000000 - | 000.00 |
| 0000000 0000000000 | Venture Capital-Backed | Bedford, MA | 000.00 | 0000000000 0 | 000.00 |
SIRPant Immunotherapeutics Executive Team (3)
SIRPant Immunotherapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialSIRPant Immunotherapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| BioAdvance | Venture Capital | Minority | 000 0000 | 000000 0 |